Melanoma susceptibility as a complex trait: Genetic variation controls all stages of tumor progression

Oncogene

Volumn 34, Issue 22, 2015, Pages 2879-2886

  Ferguson, B ^a   Ram, R ^b   Handoko, H Y ^a   Mukhopadhyay, P ^a   Muller, H K ^c   Soyer, H P ^d   Morahan, G ^b   Walker, G J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; ENDOPHENOTYPE; GENE MUTATION; GENETIC TRAIT; GENETIC VARIABILITY; MELANOGENESIS; MELANOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RISK FACTOR; SUN EXPOSURE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CANCER STAGING; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MULTIFACTORIAL INHERITANCE; MUTATION; NEVUS; PATHOLOGY; SKIN TUMOR; TRANSGENIC MOUSE;

MUS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIFACTORIAL INHERITANCE; MUTATION; NEOPLASM STAGING; NEVUS; SKIN NEOPLASMS;

EID: 84930088305     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.227     Document Type: Article

References (38)

1. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.
2. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.
3. Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol 2012; 132: 1763-1774.
4. Nadeau J. Modifier genes in mice and humans. Nat Rev Genet 2001; 2: 165-174.
5. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004; 36: 1133-1137.
6. Morahan G, Balmer L, Monley D. Establishment of 'The Collaborative Cross': a resource for rapid identification of complex trait genes. Mamm Genome 2008; 19: 390-393.
7. Welsh CE, Miller DR, Manly KF, Wang J, McMillan L, Morahan G et al. Status and access to the Collaborative Cross population. Mamm Genome 2010; 23: 706-712.
8. Threadgill DW, Churchill GA. Ten years of the collaborative cross. G3 (Bethesda) 2012; 2: 153-156.
9. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998; 77: 640-644.
10. Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW et al. The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 2008; 25: 357-369.
11. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW et al. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet 2012; 8: e1002926.
12. Winter SF, Lukes L, Walker RC, Welch DR, Hunter KW. Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. PLoS Genet 2012; 8: e1002735.
13. Abel EL, Angel JM, Riggs PK, Langfield L, Lo HH, Person MD et al. Evidence that Gsta4 modifies susceptibility to skin tumor development in mice and humans. J Natl Cancer Inst 2010; 102: 1663-1675.
14. Ferguson B, Konrad Muller H, Handoko HY, Khosrotehrani K, Beermann F, Hacker E et al. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. Pigment Cell Melanoma Res 2010; 23: 771-780.
15. Wurm ET, Ferguson B, Li L, Lambie D, Walker GJ, Soyer HP et al. Histopathologic and clinical variability in melanocytic lesions developing in genetically modified Cdk4R24C/R24C::Tyr-Nras mice. Exp Dermatol 2012; 21: 676-681.
16. Lynch HT, Fusaro RM, Pester J, Lynch JF. Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br J Cancer 1980; 42: 58-70.
17. Lee JH, Choi JW, Kim Y. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-784.
18. Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet 1997; 101: 359-364.
19. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W et al. Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum Genet 2008; 16: 1135-1141.
20. Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry D, Sagebiel R et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 2002; 12: 51-55.
21. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chrom Cancer 2005; 44: 10-18.
22. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009; 41: 915-919.
23. Le Fur N, Kelsall SR, Mintz B. Base substitution at different alternative splice donor sites of the tyrosinase gene in murine albinism. Genomics 1996; 37: 245-248.
24. Walker GJ. Cutaneous melanoma: how does ultraviolet light contribute to melanocyte transformation? Future Oncol 2008; 4: 841-856.
25. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003; 34: 108-112.
26. Quigley D, Balmain A. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet 2009; 10: 651-657.
27. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5: e120.
28. Walker GJ, Soyer HP, Terzian T, Box NF. Modelling melanoma in mice. Pigment Cell Melanoma Res 2011; 24: 158-176.
29. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-263.
30. Campagne C, Reyes-Gomez E, Battistella M, Bernex F, Château-Joubert S, Huet H et al. Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K);Cdkn2a(?/? ) transgenic mice. Pigment Cell Melanoma Res 2013; 26: 735-742.
31. Landsberg J, Gaffal E, Cron M, Kohlmeyer J, Renn M, Tüting T et al. Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance. Pigment Cell Melanoma Res 2010; 23: 649-660.
32. Chai E, Ferguson B, Prow T, Soyer HP, Walker GJ. Three-dimensional modelling for estimation of nevus count and probability of nevus-melanoma progression in a murine model. Pigment Cell Melanoma Res 2013; 27: 317-319.
33. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 2008; 58: S129-S132.
34. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95: 806-812.
35. Aoki H, Hara A, Motohashi T, Kunisada K. Functionally distinct melanocyte populations revealed by reconstitution of hair follicles in mice. Pigment Cell Melanoma Res 2011; 24: 125-135.
36. Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L et al. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. Future Oncol 2013; 9: 245-253.
37. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in betaislet cell hyperplasia. Nat Genet 1999; 22: 44-52.
38. Ackermann J, Frutschi M, Kaloulis K, Mckee T, Trumpp A, Beermann F et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005; 65: 4005-4011.